Abstract
The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDSrelated non-Hodgkin lymphoma and Multicentric Castlemans disease.
Keywords: AIDS, AIDS related Lymphoma, HAART, HIV, JC Polyoma virus associated progressive multifocal leukoencyphalopathy, Multicentric castleman's disease, non-hogdkin's lymphoma, rituximab, lymphoma, hepatitis B, hepatitis C, dose adjusted EPOCH, CHOP, CODOX-IVAC, magrath regimen, kaposi sarcoma, bortezomib
Current Drug Delivery
Title: Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Volume: 9 Issue: 1
Author(s): Erin Reid, Ajay Nooka, Jawaunna Blackmon and Mary Jo Lechowicz
Affiliation:
Keywords: AIDS, AIDS related Lymphoma, HAART, HIV, JC Polyoma virus associated progressive multifocal leukoencyphalopathy, Multicentric castleman's disease, non-hogdkin's lymphoma, rituximab, lymphoma, hepatitis B, hepatitis C, dose adjusted EPOCH, CHOP, CODOX-IVAC, magrath regimen, kaposi sarcoma, bortezomib
Abstract: The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDSrelated non-Hodgkin lymphoma and Multicentric Castlemans disease.
Export Options
About this article
Cite this article as:
Reid Erin, Nooka Ajay, Blackmon Jawaunna and Jo Lechowicz Mary, Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease, Current Drug Delivery 2012; 9 (1) . https://dx.doi.org/10.2174/156720112798376005
DOI https://dx.doi.org/10.2174/156720112798376005 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diazenyl Derivatives as Therapeutic and Diagnostic Agents Acting on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Proteolytic Cleavage of Notch: “HIT and RUN”
Current Molecular Medicine Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Current Cancer Therapy Reviews Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Formulation and Evaluation of Rifampicin Liposomes for Buccal Drug Delivery
Current Drug Delivery Circulating MicroRNAs: Valuable Biomarkers for the Diagnosis and Prognosis of Gastric Cancer
Current Medicinal Chemistry Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Current Medicinal Chemistry TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Current Medicinal Chemistry The Molecular Targets of Antitumor 2-deoxycytidine Analogues
Current Drug Targets Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology Interstitial Lung Disease in Systemic Lupus Erythematosus, Sjogren’s Syndrome, and Mixed Connective Tissue Disease
Current Respiratory Medicine Reviews Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Immunity to Tumour Antigens
Current Pharmaceutical Design ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc
Anti-Cancer Agents in Medicinal Chemistry